TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38729343

Group type: EXPERIMENTAL
Intervention: Intraventricular blood stasis imaging
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Echocardiography combining stasis and strain imaging
Number of subjects: 66
Study: 38729390

Group type: EXPERIMENTAL
Intervention: Fructans
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: FODMAP reintroduction
Number of subjects: 45
Study: 38729393

Group type: EXPERIMENTAL
Intervention: Low fermentable oligo-, mono-, di-saccharides, and polyols (FODMAPs) diet (LFD)
Number of subjects: 0
Study: 38729399

Group type: EXPERIMENTAL
Intervention: Cotadutide 600 μg
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cotadutide 300 μg
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 38729426

Group type: EXPERIMENTAL
Intervention: Subcutaneous atezolizumab (1875 mg)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Intravenous atezolizumab (1200 mg)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration
Number of subjects: 371

Group type: COMPARATOR
Intervention: Intravenous administration
Number of subjects: 371
Study: 38729550

Group type: EXPERIMENTAL
Intervention: Sapien 3/Sapien 3 Ultra Transcatheter Heart Valve (THV) series
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Myval/Myval Octacor THV series
Number of subjects: 1062
Study: 38729567

Group type: EXPERIMENTAL
Intervention: Camizestrant monotherapy at doses of 25-450 mg once daily (QD)
Number of subjects: 108
Study: 38729603

Group type: EXPERIMENTAL
Intervention: Transdiagnostic Sleep and Circadian Intervention (TranS-C)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Both TranS-C and PE
Number of subjects: 176
Study: 38729628

Group type: EXPERIMENTAL
Intervention: Baseline clinical findings (discomfort during active knee extension test)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Time to return to play (RTP)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Straight leg raise angle on the injured leg
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Presence of discomfort during active knee extension test
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Extent of oedema anteroposterior on MRI
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Myotendinous junction (MTJ) involvement on MRI
Number of subjects: 330
Study: 38729636

Group type: EXPERIMENTAL
Intervention: Spironolactone 25-50 mg/day
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control (usual therapy without spironolactone)
Number of subjects: 290
Study: 38729746

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 17
Study: 38729747

Group type: EXPERIMENTAL
Intervention: Rozanolixizumab 10 mg/kg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Number of subjects: 34
Study: 38729748

Group type: EXPERIMENTAL
Intervention: Erythropoietin (500 U/kg daily) for 9 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (sham injections)
Number of subjects: 50
Study: 38729754

Group type: EXPERIMENTAL
Intervention: Conservative treatment with reconstructive lymphatic surgery
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conservative treatment alone (control group)
Number of subjects: 180
Study: 38729756

Group type: EXPERIMENTAL
Intervention: Vaginal cerclage
Number of subjects: 238

Group type: COMPARATOR
Intervention: Standard treatment (no cerclage)
Number of subjects: 238
Study: 38729773

Group type: EXPERIMENTAL
Intervention: NN414
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 38729814

Group type: EXPERIMENTAL
Intervention: Ex-Care BR model
Number of subjects: 107372
Study: 38729818

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (569,600 IU)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 38729951

Group type: EXPERIMENTAL
Intervention: Fosfomycin, flomoxef, and amikacin (combination regimens)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current WHO recommended empiric regimens (ampicillin, gentamicin, cefotaxime)
Number of subjects: 0
Study: 38730030

Group type: EXPERIMENTAL
Intervention: Guided internet-delivered psychodynamic therapy (IPDT)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Unguided internet-delivered psychodynamic therapy (IPDT)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Guided and unguided internet-delivered psychodynamic therapy (IPDT)
Number of subjects: 181
Study: 38730089

Group type: EXPERIMENTAL
Intervention: Acute urosepsis with SOFA score ≥ 2 at diagnosis
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Patients with respiratory failure at baseline
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: ICU admission within the past 12 months
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Obstruction causative of urosepsis
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Urosepsis with multi-drug-resistant (MDR) pathogens
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: SOFA baseline score ≥ 2
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 354
Study: 38730096

Group type: EXPERIMENTAL
Intervention: Perampanel (monotherapy)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Perampanel (first adjunctive therapy)
Number of subjects: 54
Study: 38730247

Group type: EXPERIMENTAL
Intervention: Lanifibranor
Number of subjects: 0
Study: 38730343

Group type: EXPERIMENTAL
Intervention: Serological multiplex assays based on various antigen targets and antibody properties.
Number of subjects: 0
Study: 38730363

Group type: EXPERIMENTAL
Intervention: High adherence to the Mediterranean Diet Adherence Screener (MEDAS) score (≥9 points)
Number of subjects: 4573

Group type: EXPERIMENTAL
Intervention: High adherence to the Alternative Healthy Eating Index (AHEI-2010) (quartile 4)
Number of subjects: 4573

Group type: EXPERIMENTAL
Intervention: Higher consumption of fish and long-chain n-3 fatty acids (from MEDAS and AHEI-2010)
Number of subjects: 4573

Group type: EXPERIMENTAL
Intervention: Higher consumption of vegetables, nuts, and legumes (from AHEI-2010)
Number of subjects: 4573

Group type: EXPERIMENTAL
Intervention: Lower intake of trans-fat, sugar-sweetened beverages, and fruit juice (from AHEI-2010)
Number of subjects: 4573
Study: 38730383

Group type: EXPERIMENTAL
Intervention: Intermittent electrical stimulation (IES) combined with routine care
Number of subjects: 548

Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 548
Study: 38730382

Group type: EXPERIMENTAL
Intervention: On-site Supportive Communication Training (On-site SCT) for three full days facilitated by a trained psychologist.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: On-site Supportive Communication Training (On-site SCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study: 38730398

Group type: EXPERIMENTAL
Intervention: Pharmacy-based PrEP refills
Number of subjects: 106

Group type: COMPARATOR
Intervention: Clinic-delivered PrEP services
Number of subjects: 106
Study: 38730407

Group type: EXPERIMENTAL
Intervention: Walking school bus intervention
Number of subjects: 418

Group type: COMPARATOR
Intervention: Control (education materials)
Number of subjects: 418
Study: 38730496

Group type: EXPERIMENTAL
Intervention: lecanemab 10 mg/kg biweekly
Number of subjects: 1795

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1795

Group type: EXPERIMENTAL
Intervention: lecanemab
Number of subjects: 1795
Study: 38730548

Group type: EXPERIMENTAL
Intervention: Liver-directed radiotherapy with escalating functional liver radiation dose constraints (prescription dose 67.5-75 Gy in 15 fractions or 75-100 Gy in 25 fractions)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Liver-directed radiotherapy
Number of subjects: 12
Study: 38732635

Group type: EXPERIMENTAL
Intervention: Probiotic preparation
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 116
Study: 38733160

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (titrated to the maximum dose of 97/103 mg twice daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 38733253

Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: NYHA class III/IV
Number of subjects: 1116
Study: 38733340

Group type: EXPERIMENTAL
Intervention: Azathioprine 150 mg/day and hydroxyurea 25 mg/kg/day for 3 months prior to alemtuzumab 1 mg/kg and 300 cGy TBI conditioning
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Azathioprine/hydroxyurea preconditioning
Number of subjects: 20
Study: 38733387

Group type: EXPERIMENTAL
Intervention: Risdiplam
Number of subjects: 174
Study: 38733447

Group type: EXPERIMENTAL
Intervention: Beta-blocker use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Target trial emulation of REDUCE-AMI
Number of subjects: 0
Study: 38733554

Group type: EXPERIMENTAL
Intervention: NINJ1 expression levels in the TCGA cohort
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: NINJ1 expression levels in the validation cohort
Number of subjects: 135
Study: 38734015

Group type: EXPERIMENTAL
Intervention: Doravirine (100 mg) and Islatravir (0·75 mg)
Number of subjects: 672

Group type: COMPARATOR
Intervention: Baseline ART
Number of subjects: 672
Study: 38734016

Group type: EXPERIMENTAL
Intervention: Doravirine (100 mg) and Islatravir (0·75 mg)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Bictegravir, Emtricitabine, and Tenofovir Alafenamide
Number of subjects: 643
Study: 38734047

Group type: EXPERIMENTAL
Intervention: Alternating hot-cold water immersion (AHCWI)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Upper limb (UL) cycling exercises
Number of subjects: 24
Study: 38734048

Group type: EXPERIMENTAL
Intervention: Decannulated patients
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Consciousness states at decannulation
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Improvement in consciousness
Number of subjects: 144
Study: 38734133

Group type: EXPERIMENTAL
Intervention: Cognitive tests and neuropsychological assessments
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Participants with comorbid ADHD (n=64)
Number of subjects: 551

Group type: COMPARATOR
Intervention: General population of males with hemophilia
Number of subjects: 551
Study: 38734138

Group type: EXPERIMENTAL
Intervention: Intravenous treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oral treatment
Number of subjects: 200
Study: 38734383

Group type: EXPERIMENTAL
Intervention: Bulevirtide 2 mg/day for 144 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Bulevirtide 10 mg/day for 144 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Delayed treatment for 48 weeks followed by Bulevirtide 10 mg/day for 96 weeks
Number of subjects: 150
Study: 38734439

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 30
Study: 38734495

Group type: EXPERIMENTAL
Intervention: S-268019-b (10 µg, 2 doses, 28 days apart)
Number of subjects: 8594

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8594
Study: 38734654

Group type: EXPERIMENTAL
Intervention: MDSC immunosuppressive properties
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: MDSCs from peripheral blood
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Circulating immunosuppressive MDSCs
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: In vitro functional assay
Number of subjects: 61
Study: 38734659

Group type: EXPERIMENTAL
Intervention: Pedometer intervention (Sophia Step Study)
Number of subjects: 83
Study: 38734802

Group type: EXPERIMENTAL
Intervention: WISER intervention
Number of subjects: 506
Study: 38734805

Group type: EXPERIMENTAL
Intervention: Vaccinated before conception
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Vaccinated during pregnancy
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Unvaccinated
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Vaccinated before conception (infected group)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Vaccinated during pregnancy (infected group)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Vaccinated at 13-16 weeks gestation
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Vaccinated before conception (non-infected group)
Number of subjects: 83
Study: 38735015

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 5464

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 5464
Study: 38735220

Group type: EXPERIMENTAL
Intervention: SC trastuzumab (fixed dose 600 mg, q3w) administered through a hand-held syringe followed by 7 cycles of SC trastuzumab administered with an SID
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SC trastuzumab
Number of subjects: 90

Group type: COMPARATOR
Intervention: IV trastuzumab
Number of subjects: 90
Study: 38735305

Group type: EXPERIMENTAL
Intervention: S pyogenes pharyngeal carriage
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: S pyogenes skin carriage
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: S pyogenes pharyngitis
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: S pyogenes pyoderma
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Household secondary attack rate for epidemiologically linked S pyogenes events
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Household secondary attack rate for emm-linked S pyogenes events
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Carriage acquisition clearance time
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: emm-linked household transmission events
Number of subjects: 442
Study: 38735354

Group type: EXPERIMENTAL
Intervention: nirmatrelvir/ritonavir
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo/ritonavir
Number of subjects: 100
Study: 38735424

Group type: EXPERIMENTAL
Intervention: White bystander acknowledgment and apology for racial exclusion
Number of subjects: 92

Group type: COMPARATOR
Intervention: Racial exclusion (no acknowledgment)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Inclusion by White players in the ball-tossing game
Number of subjects: 92
Study: 38735574

Group type: EXPERIMENTAL
Intervention: Lysine requirement for females aged 60-69 years
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lysine requirement for females aged >70 years
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lysine requirement for males (combined groups)
Number of subjects: 30
Study: 38735912

Group type: EXPERIMENTAL
Intervention: Low-intensity electrical stimulation (LIES)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional en-masse retraction (CER)
Number of subjects: 40
Study: 38736116

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg subcutaneously every 4 weeks
Number of subjects: 100
Study: 38736216

Group type: EXPERIMENTAL
Intervention: AF-Raman instrument
Number of subjects: 130

Group type: COMPARATOR
Intervention: Intraoperative diagnosis by Mohs surgeons
Number of subjects: 130
Study: 38736628

Group type: EXPERIMENTAL
Intervention: Cognitive defusion techniques
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 38736736

Group type: EXPERIMENTAL
Intervention: Videoconference-delivered group Cognitive Behavioral Stress Management (V-CBSM)
Number of subjects: 0
Study: 38737002

Group type: EXPERIMENTAL
Intervention: Once-weekly subcutaneous semaglutide 1.0 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 38737110

Group type: COMPARATOR
Intervention: Higher PHR (PHR-H) with non-DM
Number of subjects: 56316

Group type: COMPARATOR
Intervention: Higher PHR (PHR-H) with DM
Number of subjects: 56316

Group type: COMPARATOR
Intervention: Lower PHR (PHR-L) with DM
Number of subjects: 56316
Study: 38737349

Group type: EXPERIMENTAL
Intervention: Transcranial photobiomodulation (tPBM) - Pulses of near-infrared light (40 Hz, 850 nm) delivered noninvasively twice a week for eight weeks
Number of subjects: 30
Study: 38737405

Group type: EXPERIMENTAL
Intervention: Specialized Pediatric Palliative Care (SPPC) team support
Number of subjects: 301

Group type: COMPARATOR
Intervention: Generalist PPC without SPPC support
Number of subjects: 301
Study: 38737429

Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine
Number of subjects: 144

Group type: COMPARATOR
Intervention: Tenofovir Alafenamide-based regimen
Number of subjects: 144
Study: 38737600

Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy (CIRT) with RBE-weighted fraction doses of 8.1-10.5 Gy, total doses 32.4-42.0 Gy, performed every other day in four fractions
Number of subjects: 20
Study: 38737708

Group type: EXPERIMENTAL
Intervention: Sustained-release carvedilol (carvedilol-SR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 38737762

Group type: EXPERIMENTAL
Intervention: Pressure support adjusted to obtain PMI closest to -1, 0, +1, +2, and +3 cm H2O
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pressure support adjustment according to PMI target
Number of subjects: 22
Study: 38737792

Group type: EXPERIMENTAL
Intervention: ipilimumab-containing regimens
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: nivolumab arm
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: ipilimumab-exposed cases
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: rash (irAE type)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: liver toxicity (irAE type)
Number of subjects: 112
Study: 38737891

Group type: EXPERIMENTAL
Intervention: mFICare (Mobile-enhanced Family Integrated Care)
Number of subjects: 9
Study: 38737981

Group type: EXPERIMENTAL
Intervention: Self-applied psychotherapy with psychotherapeutic telephone support
Number of subjects: 110

Group type: COMPARATOR
Intervention: Self-applied psychotherapy without telephone support (unguided)
Number of subjects: 110
Study: 38738598

Group type: EXPERIMENTAL
Intervention: Magnesium citrate 200 mg daily for 8 weeks
Number of subjects: 12
Study: 38738683

Group type: EXPERIMENTAL
Intervention: Nirsevimab
Number of subjects: 0
Study: 38738695

Group type: EXPERIMENTAL
Intervention: ABCC-tool used during routine consultations (intervention group)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 237
Study: 38738780

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 20
Study: 38739062

Group type: EXPERIMENTAL
Intervention: Percutaneous Peripheral Nerve Stimulation (PNS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (sham) stimulation
Number of subjects: 41
Study: 38739079

Group type: EXPERIMENTAL
Intervention: Aficamten (starting dose 5 mg, maximum dose 20 mg)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Aficamten
Number of subjects: 282

Group type: COMPARATOR
Intervention: Aficamten and Placebo
Number of subjects: 282
Study: 38739118

Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg once weekly for 52 weeks
Number of subjects: 1145
Study: 38739123

Group type: EXPERIMENTAL
Intervention: High-intensity care (HIC) - rapid uptitration of heart failure GDMT to 100% of recommended doses within 2 weeks of discharge and 4 scheduled outpatient visits over 2 months after discharge
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1078
Study: 38739215

Group type: EXPERIMENTAL
Intervention: Risankizumab
Number of subjects: 1407

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1407
Study: 38739305

Group type: EXPERIMENTAL
Intervention: Stepping Together for Children after Trauma (ST-CT)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Baseline PTSS and depressive symptoms
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Posttraumatic cognitions and exposure to interpersonal trauma
Number of subjects: 82
Study: 38739306

Group type: EXPERIMENTAL
Intervention: Back2School (B2S), a modular transdiagnostic cognitive behavioral therapy (CBT) for SAPs, with an average of 15.0 hours of intervention (SD=3.9) over three months.
Number of subjects: 152

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU), comprising public and/or private intervention services, with an average of 13.4 hours of intervention (SD=21.6).
Number of subjects: 152
Study: 38739382

Group type: EXPERIMENTAL
Intervention: Iron supplementation (micronized microencapsulated ferric pyrophosphate), 1 mg/kg, once daily from age 4 to 9 months.
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo (maltodextrin), once daily from age 4 to 9 months.
Number of subjects: 221
Study: 38739392

Group type: EXPERIMENTAL
Intervention: True Acupuncture (TA)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 258
Study: 38739422

Group type: EXPERIMENTAL
Intervention: Citrate-free high-concentration adalimumab-adbm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference formulation of adalimumab-adbm
Number of subjects: 0
Study: 38739429

Group type: EXPERIMENTAL
Intervention: Personalized regular messages and access to interactive chatting through IM apps for 3 months.
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Engaging in chat sessions with SC advisors within the intervention group.
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control group received 26 SMS text messages focusing on general health.
Number of subjects: 700
Study: 38739581

Group type: EXPERIMENTAL
Intervention: Couple-based violence prevention education
Number of subjects: 432

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 432
Study: 38739584

Group type: EXPERIMENTAL
Intervention: Vega PS System
Number of subjects: 84
Study: 38739615

Group type: EXPERIMENTAL
Intervention: State-of-the-art periodontal treatment during pregnancy
Number of subjects: 600

Group type: COMPARATOR
Intervention: Periodontal treatment after giving birth
Number of subjects: 600
Study: 38739766

Group type: EXPERIMENTAL
Intervention: Genetic ablation of mechanoreceptors before SCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genetic ablation of mechanoreceptors after SCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin-nerve preparations of contusion SCI mice 7 days after injury
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing in human SCI subjects
Number of subjects: 0